Haoyuan Pharmaceutical: Plans to Temporarily Postpone a Project and Change the Use of 200 Million Yuan in Raised Funds

Haoyuan Pharmaceutical announced that in order to improve the efficiency of fund utilization, the company has decided to postpone the construction of the industrialization project for high-end pharmaceutical intermediates and active pharmaceutical ingredients CDMO, reducing the proposed investment from 373 million yuan to 173 million yuan. The 200 million yuan reduction will be loaned to Chongqing Haoyuan for the "Haoyuan Pharmaceutical Antibody-Drug Conjugate CDMO Base Project - Antibody Formulation Expansion Project." This matter has been approved by the board of directors and is pending submission for review by the shareholders' meeting and the convertible bondholders' meeting.